Regression of liver fibrosis in patients with chronic hepatitis C after a cycle of therapy with direct-acting antivirals

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To assess the time course of changes in liver fibrosis (LF) in patients with chronic hepatitis C (CHC) who received a cycle of therapy with direct-acting antivirals.

Subjects and methods. Fifty-nine patients with CHC and different stages of LF, who received therapy with direct-acting antivirals according to different treatment regimens for 8 to 16 weeks, were followed up. In all the patients, the time course of changes in liver tissue fibrosis was retrospectively analyzed based on fibroscanning results. The stage of fibrosis was diagnosed using vibration-controlled transient elastometry; the degree of steatosis was assessed by the controlled attenuation parameter using the FibroScan® 530 Compact device, Echosens (France).

Results. According to the METAVIR scoring system, fibrosis stage F4 was established in 24 (40.7%) patients before the start of antiviral therapy for CHC; it persisted in 7 (11.9%) after the end of treatment.

Conclusion. The findings suggest that the stage of LF is reversed after completion of an antiviral therapy cycle.

Full Text

Restricted Access

About the authors

Yana E. Saranskaya

Ulyanovsk State University

Author for correspondence.
Email: ms.saranskaya@mail.ru
ORCID iD: 0000-0001-8498-9554

Assistant Lecturer, Department of Infectious and Skin and Venereal Diseases

Russian Federation, Ulyanovsk

Lyubov M. Kiseleva

Ulyanovsk State University

Email: kiseleva.l.m.73@mail.ru
ORCID iD: 0000-0003-1188-7682

MD, Professor, Department of Infectious and Skin and Venereal Diseases

Russian Federation, Ulyanovsk

Anna A. Sachek

Ulyanovsk State University

Email: sachek.a.15@mail.ru
ORCID iD: 0000-0003-4776-7869

Sixth-Year Student, Faculty of Medicine

Russian Federation, Ulyanovsk

References

  1. Корнилова Е.Б., Ермолаева А.Д., Русанова М.Г., Андреев Д.А., Давыдовская М.В., Ермолаева Т.Н. и др. Стратегии лекарственного обеспечения пациентов с хроническим вирусным гепатитом С. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология 2017; 10(3): 34–46. doi: 10.17749/2070-4909.2017.10.3.034-046. Kornilova E.V., Ermolaeva A.D., Rusanova M.G., Andreev D.A., Davydovskaya M.V., Ermolaeva T.N. et al. [The strategies of drug supply for patients with chronic hepatitis C. Farmakoekonomika]. Modern Pharmacoeconomics and Pharmacoepidemiology 2017; 10(3): 34–46. (In Russ.). doi: 10.17749/2070-4909.2017.10.3.034-046.
  2. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 Lancet Gastroenterol Hepatol 2020; (5): 245–66. DOI:10.1016/ S2468-1253(19)30349-8 р.245-266.
  3. Пименов Н.Н., Комарова С.В., Карандашова И.В., Цапкова Н.Н., Волчкова Е.В., Чуланов В.П. Гепатит С и его исходы в России: анализ заболеваемости распространенности и смертности до начала программы элиминации инфекции. Инфекционные болезни 2018; 16(3): 37–45. doi: 10.20953/1729-9225-2018-3-37-45. Pimenov N.N., Komarova S.V., Karandashova I.V., Tsapkova N.N., Volchkova E.V., Chulanov V.P. [Hepatitis C and its outcomes in Russia: an analysis of morbidity, prevalence and mortality before the start of the infection elimination program]. Infectious Diseases 2018; 16(3): 37–45. (In Russ.). doi: 10.20953/1729-9225-2018-3-37-45.
  4. SECURE-Cirrhosis COVID-HEP Combined. https://covidcirrhosis.web. unc.edu/files/2020/07/Weekly-Data-Update-5-July-2020
  5. Teti E., Ricciardi A., Antinori A., Galli M., Rizzardini G., Di Biagio A. et al. Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection: Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program. J. Hepatol. 2016; 64(2): 763. doi: 10.1016/S0168-8278(16)01487-2
  6. Christensen S., Ingiliz P., Schewe K., Rockstroh J., Hueppe D., Baumgarten A. et al. Relapse and Treatment-Emergent RAVS with DAA-Based Regimens in Hepatitis C Virus (HCV) Mono- or Human Immunodeficiency Virus (HIV)-HCV Co-Infected Patients – a Real Concern in Clinical Practice? Results from the German Hepatitis C Cohort (GECCO). J. Hepatol. 2016; 64(2): 821. doi: 10.1016/S0168-8278(16)01605-6
  7. Sarrazin C., Isakov V., Svarovskaia E.S., Hedskog C., Martin R., Chodavarapu K. et al. Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after sofosbuvir-based therapies. Clin. Infec.t Dis. 2017; 64: 44–52. doi: 10.1093/cid/ciw676
  8. Carrat F., Fontaine H., Dorival C., Simony M., Diallo A., Hezode C. et al. French ANRS CO22 Hepather cohort. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 2019; 393(10179): 1453–64. doi: 10.1016/S0140-6736(18)32111-1
  9. Mandorfer M., Kozbial K., Schwabl P., Chromy D., Semmler G., Stattermayer A.F. et al. Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interfer-on-free therapy. Hepatology 2020; 71(3): 1023–36. doi: 10.1002/hep.3088
  10. Mauro E., Crespo G., Montironi C., Londono M.C., Hernandez-Gea V., Ruiz P. et al. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Hepatology 2018; 67(5): 1683–94. doi: 10.1002/hep.29557
  11. FibroScan & FibroMeter Clinical Handbook Main publications by etiologies & applications, 2017. http://www.echosens.com
  12. Морозов В.Г., Фролов А.В., Топорнина Л.М., Синельников М.И., Жаркова Е.В., Рыбкина А.А. и др. Эффективность и безопасность противовирусной терапии паритапревир/ритонавир + омбитасвир + дасабувир + рибавирин у больных циррозом печени в исходе хронического гепатита С. Инфекционные болезни 2016; 14(4): 37–43. doi: 10.20953/1729-9225-2016-4-37-43. Morozov V.G., Frolov A.V., Topornina L. M., Sinelnikov M. I., Zharkova E.V., Rybkina A.A. et al. [Efficacy and safety of antiviral therapy Paritaprevir/ritonavir + Ombitasvir + Dasabuvir + Ribavirin in patients with liver cirrhosis in the outcome of chronic hepatitis C]. Infectious Diseases 2016; 14(4): 37–43. (In Russ.). doi: 10.20953/1729-9225-2016-4-37-43
  13. Davidov Y., Kleinbaum Y., Cohen-Ezra O., Veitsman E., Berdichevski T. et al. Regression of Liver Fibrosis assessed by non-invasive methods in Patients with Chronic Hepatitis C who Achieved Sustained Virologic Response after DAAs Treatment. J. Hepatol. 2016; 64(1): 824–70.
  14. Hametner S., Schwarzer R., Ziachehabi A., Schöfl R., Maieron A. Gastroenterology and Hepatology, Elisabeth Hospital, Linz, Austria. Regression of fibrosis in HCV patients treated with direct acting antivirals (DAAs). J. Hepatol. 2016; 64(1): 958.
  15. Макашова В.В., Омарова Х.Г., Понежева Ж.Б. Эффективность препаратов прямого противовирусного действия у больных хроническим гепатитом С. Евразийский Союз Ученых (ЕСУ) 2019; 8(65): 47–9. doi: 10.31618/ESU.2413-9335.2019.1.65.257
  16. Жданов К.В., Козлов К.В., Сукачев В.С., Захаренко С.М., Карякин С.С., Саулевич А.В. Элиминация HCV-инфекции: история с продолжением. Журнал инфектологии 2018; 10(4): 6–13. doi: 10.22625/2072–6732–2018–10–4–6–13. Zhdanov K.V., Kozlov K.V., Sukachev V.S., Zakharenko S.M., Karyakin S.S., Saulevich A.V. et al. [Elimination of HCV infection: a story with continuation]. J. Infectol. 2018; 10(4): 6–13 (In Russ.). DOI: 10.22625/ 2072-6732-2018-10-4-6-13
  17. Эсауленко Е.В., Новак К.Е., Басина В.В., Дземова А.А., Ганченко Р.А. Распространенность коморбидности при хроническом вирусном гепатите С. Медицинский алфавит 2021; (1): 66–70. doi: 10.33667/2078- 5631-2021-1-66-70. Esaulenko E.V., Novak K.E., Basina V.V., Dzemova A.A., Ganchenko R.A. [The prevalence of comorbidity in chronic viral hepatitis C]. Medical alphabet 2021; (1): 66–70 (In Russ.). doi: 10.33667/2078-5631-2021-1-66-70

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies